Displaying 1 publication

Abstract:
Sort:
  1. Cheong SL, Tiew JK, Fong YH, Leong HW, Chan YM, Chan ZL, et al.
    Pharmaceuticals (Basel), 2022 Dec 14;15(12).
    PMID: 36559010 DOI: 10.3390/ph15121560
    Alzheimer's disease (AD) is a neurodegenerative disorder characterized by decreased synaptic transmission and cerebral atrophy with appearance of amyloid plaques and neurofibrillary tangles. Cognitive, functional, and behavioral alterations are commonly associated with the disease. Different pathophysiological pathways of AD have been proposed, some of which interact and influence one another. Current treatment for AD mainly involves the use of therapeutic agents to alleviate the symptoms in AD patients. The conventional single-target treatment approaches do not often cause the desired effect in the disease due to its multifactorial origin. Thus, multi-target strategies have since been undertaken, which aim to simultaneously target multiple targets involved in the development of AD. In this review, we provide an overview of the pathogenesis of AD and the current drug therapies for the disease. Additionally, rationales of the multi-target approaches and examples of multi-target drugs with pharmacological actions against AD are also discussed.
Related Terms
Filters
Contact Us

Please provide feedback to Administrator ([email protected])

External Links